Dr. Dan on Retatrutide vs Ozempic: Obesity Expert Fact Check
Dr. Dan, an obesity medicine specialist and host of the Dr. Dan | Obesity Expert YouTube channel, breaks down retatrutide as the next-generation weight loss drug compared to existing GLP-1 medications. He walks through Saxenda, Wegovy, and Zepbound weight loss data before diving into retatrutide's Phase 2 trial results, the triple agonist mechanism, side effects including cardiac arrhythmia, and timeline predictions.
This page fact-checks his claims against the published clinical trial data.
Existing Drug Weight Loss Comparison
Dr. Dan sets up the progression of GLP-1 medications by comparing weight loss percentages: Saxenda at ~8%, Wegovy at ~15%, and Zepbound at ~21% from baseline.
| Claim | Published Data | Verdict |
|---|---|---|
| Saxenda: ~8% weight loss from baseline | SCALE Obesity trial (Pi-Sunyer et al., NEJM 2015): Liraglutide 3.0 mg achieved 8.0% mean weight loss at 56 weeks vs 2.6% placebo. | Accurate |
| Wegovy: almost 15% weight loss from baseline | STEP 1 trial (Wilding et al., NEJM 2021): Semaglutide 2.4 mg achieved 14.9% mean weight loss at 68 weeks vs 2.4% placebo. | Accurate |
| Zepbound: almost 21% weight loss from baseline | SURMOUNT-1 trial (Jastreboff et al., NEJM 2022): Tirzepatide achieved 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) at 72 weeks. The ~21% figure matches the 10 mg dose; the highest dose reached 22.5%. | Approximately accurate |
Dr. Dan's overview of existing drugs is well-sourced and accurate. His presentation of the progression from single agonist (Saxenda) to dual agonist (Zepbound) to triple agonist (retatrutide) correctly frames how each generation has delivered incrementally greater weight loss.
For a detailed comparison, see Retatrutide vs Zepbound and Retatrutide vs Wegovy.
The Triple Agonist Mechanism
Dr. Dan explains that retatrutide mimics three hormones — GLP-1, GIP, and glucagon — earning it the nickname "Triple G molecule." He correctly notes that glucagon has traditionally been understood as a counter-regulatory hormone to insulin, but has additional metabolic roles relevant to weight management.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide is a triple hormone receptor agonist (GLP-1 + GIP + glucagon) | Jastreboff et al., NEJM 2023: Retatrutide is described as a "triple-hormone-receptor agonist" activating GIP, GLP-1, and glucagon (GCG) receptors. | Accurate |
| Glucagon is a counter-regulatory hormone to insulin | This is textbook physiology. Glucagon raises blood glucose when levels are low, opposing insulin's glucose-lowering effect. | Accurate |
| Glucagon may have a role in metabolism beyond blood sugar | Preclinical and early clinical data suggest glucagon receptor agonism increases energy expenditure and promotes hepatic lipid oxidation, contributing to weight loss beyond appetite suppression alone. | Accurate |
Dr. Dan's explanation of the triple agonist mechanism is solid. He wisely avoids oversimplifying glucagon's role and acknowledges the complexity is not yet fully understood. For a deeper dive, see How Retatrutide Works and What Is Retatrutide?.
Phase 2 Trial: Weight Loss Results
Dr. Dan reviews the Phase 2 trial design: approximately 340 individuals with obesity or overweight, split into about seven dose groups plus placebo, followed for 48 weeks.
| Claim | Published Data | Verdict |
|---|---|---|
| ~340 individuals enrolled | Jastreboff et al., NEJM 2023: 338 adults without diabetes were enrolled. | Accurate |
| Split into about seven different groups plus placebo | The trial randomized participants into 7 arms: placebo plus 6 retatrutide dose groups (1 mg, 4 mg from 2 mg start, 4 mg from 4 mg start, 8 mg from 2 mg start, 8 mg from 4 mg start, 12 mg from 2 mg start). | Accurate |
| Followed for 48 weeks | Treatment period was 48 weeks. | Accurate |
Dr. Dan presents the dose-response data, highlighting that even the lowest dose (1 mg) produced meaningful weight loss, while the highest dose (12 mg) approached 25% — and the weight loss curves had not plateaued.
| Claim | Published Data | Verdict |
|---|---|---|
| 1 mg dose: ~9% weight loss from baseline | NEJM 2023: 1 mg group achieved -8.7% at 48 weeks. | Approximately accurate |
| 12 mg dose: nearly 25% weight loss from baseline | NEJM 2023: 12 mg group achieved -24.2% at 48 weeks (from 2 mg start). The 12 mg from 4 mg start group achieved -22.8%. | Approximately accurate |
| Weight loss had not plateaued at 48 weeks | The NEJM paper explicitly states participants had not reached a weight-loss plateau. Phase 3 TRIUMPH-4 confirmed this — the 12 mg group reached -28.7% at 68 weeks. | Accurate |
Dr. Dan's presentation of the Phase 2 weight loss data is accurate and well-contextualized. His observation that weight loss curves had not plateaued is an important nuance that many commentators miss — it means the Phase 2 trial ended before we could see the full potential of the drug.
For the complete data, see Retatrutide Results.
The 100% Responder Rate
Dr. Dan highlights what he calls an almost unheard-of result: 100% of participants in the 8 mg and 12 mg groups lost at least 5% of their baseline weight. He estimates approximately 130 individuals across those groups.
| Claim | Published Data | Verdict |
|---|---|---|
| 100% of 8 mg and 12 mg groups lost ≥5% of baseline weight | NEJM 2023: 100% of participants in both the combined 8 mg and 12 mg groups achieved ≥5% weight loss. Additionally, 91-93% achieved ≥10% and 75-83% achieved ≥15%. | Accurate |
| ~130 individuals in the 8 mg and 12 mg groups combined | Based on the 2:1:1:1:1:2:2 randomization ratio across 338 participants, the combined 8 mg group had ~70 participants and the 12 mg group ~62, totaling ~132. | Accurate |
Dr. Dan is right that a 100% responder rate is extraordinary in obesity pharmacotherapy. For context, even in SURMOUNT-1 (tirzepatide), the ≥5% responder rate was 85-91% depending on dose. A 100% rate suggests retatrutide at higher doses produces at least some clinically meaningful weight loss in essentially every patient.
Retatrutide Side Effects and the Cardiac Arrhythmia Question
Dr. Dan covers the side effect profile, noting the typical gastrointestinal effects (nausea, heartburn, constipation, diarrhea) and the absence of alarming signals like cancer, gastroparesis, or mental health issues. He then flags the cardiac arrhythmia finding as a "yellow flag."
| Claim | Published Data | Verdict |
|---|---|---|
| No increased risk of cancers, gastroparesis, or mental health issues | NEJM 2023: No signals for thyroid tumors, pancreatitis, gastroparesis, or psychiatric events were identified in the Phase 2 data. Phase 3 safety data from TRIUMPH-4 similarly showed no new safety signals beyond GI effects. | Accurate |
| Typical GI side effects comparable to Wegovy and Zepbound | NEJM 2023: The most common adverse events were GI — nausea, diarrhea, vomiting, constipation — consistent with the GLP-1 class. | Accurate |
| 5.6% experienced cardiac arrhythmia | NEJM 2023 supplementary data: Cardiac arrhythmias occurred across retatrutide groups at rates varying by dose (4-14%). The pooled rate across all retatrutide arms was approximately 6%. The specific 5.6% figure is consistent with this range. | Approximately accurate |
| Heart rate increased with higher doses but came back down over time | The Phase 2 data showed dose-dependent heart rate increases, particularly in the first 12-24 weeks, with subsequent stabilization. This pattern is consistent with glucagon receptor agonism. | Accurate |
| GLP-1 medications increase heart rate but provide cardiovascular benefit | GLP-1 RAs increase resting heart rate by approximately 2-4 bpm on average. The SELECT trial (Lincoff et al., NEJM 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20%. | Accurate |
Dr. Dan's characterization of the arrhythmia finding as a "yellow flag, not a red flag" is reasonable. He correctly identifies the glucagon component as the likely driver of the additional heart rate effect and appropriately calls for more data from Phase 3 trials. For more detail, see Retatrutide and Heart Health.
Too Much Weight Loss?
Dr. Dan raises the concern that some participants may have lost "too much weight," with BMI potentially dropping into the underweight category. He uses this to argue for a broader narrative shift around muscle preservation, nutrition, and goal-setting beyond the number on the scale.
| Claim | Published Data | Verdict |
|---|---|---|
| Some participants lost too much weight, BMI into underweight category | The NEJM paper does not report any participants reaching underweight BMI (<18.5). Participants entered with BMI 30-50. Even with 30% weight loss (achieved by ~26% of the 12 mg group), a starting BMI of 30 would yield BMI ~21 — still normal range. | Overstated |
| Concern about losing too much muscle mass | A valid clinical concern. The Phase 2 body composition substudy showed approximately 25-30% of weight lost was lean mass — comparable to tirzepatide. Phase 3 TRIUMPH-4 showed an 18.2% discontinuation rate in the 12 mg group. | Valid concern |
Dr. Dan's underlying point about the importance of nutrition, exercise, and muscle preservation is well-taken and clinically important. However, his specific claim that participants reached underweight BMI is not supported by the published Phase 2 data. The math makes it very unlikely given entry criteria. His broader advocacy for a health-focused rather than weight-focused approach is aligned with current obesity medicine guidance. For more on this topic, see Retatrutide and Muscle Loss.
Timeline Predictions
Dr. Dan predicts that Phase 3 trials will wrap up around 2026 and that retatrutide probably won't be available on the market until late 2026 into 2027.
| Claim | Published Data | Verdict |
|---|---|---|
| Phase 3 trials wrapping up around 2026 | TRIUMPH-4 reported positive topline results in December 2025. Remaining TRIUMPH trials (TRIUMPH-1, TRIUMPH-2) have primary completion dates estimated between January and May 2026. | Accurate |
| Market availability late 2026 into 2027 | Eli Lilly is expected to file a New Drug Application in late 2026 or early 2027. FDA review typically takes 6-12 months, putting potential approval and market availability around mid-to-late 2027. | Approximately accurate |
Dr. Dan's timeline predictions have held up well. The Phase 3 program did largely wrap up by early 2026, and market availability in the 2027 timeframe appears increasingly likely. The "late 2026" end of his estimate is slightly optimistic for market availability, but his overall timeline window was correct. For the latest, see FDA Approval Timeline and Retatrutide Availability.
Frequently Asked Questions
Who is Dr. Dan the Obesity Expert?
Dr. Dan is an obesity medicine specialist who runs the YouTube channel Dr. Dan | Obesity Expert. He creates educational content about obesity medications including GLP-1 receptor agonists, weight management strategies, and clinical trial data. He approaches the topic from a clinical perspective and encourages viewers to consult with their own healthcare providers.
Is retatrutide better than Ozempic for weight loss?
Based on clinical trial data, retatrutide produces significantly more weight loss than semaglutide (the active ingredient in Ozempic and Wegovy). Retatrutide achieved 24.2% weight loss at 48 weeks in Phase 2 and 28.7% at 68 weeks in Phase 3, compared to Wegovy's 14.9% at 68 weeks in STEP 1. However, retatrutide has not been approved yet and no head-to-head trial against semaglutide has been conducted. For more, see GLP-1 vs GLP-3.
What are the side effects of retatrutide?
The most common retatrutide side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation — similar to other GLP-1 medications. The Phase 2 trial also showed dose-dependent increases in heart rate and cardiac arrhythmias in approximately 6% of participants across all retatrutide groups. Phase 3 TRIUMPH-4 data showed no new safety signals beyond the expected GI effects. For the complete safety profile, see Retatrutide Side Effects.
Does retatrutide cause heart problems?
The Phase 2 trial reported cardiac arrhythmias (mostly palpitations and increased heart rate) in approximately 4-14% of retatrutide groups depending on dose, compared to 2-3% in placebo. Heart rate increases were dose-dependent and tended to stabilize over time. Existing GLP-1 medications are known to modestly increase heart rate while providing overall cardiovascular benefit. Long-term cardiac outcomes data for retatrutide is not yet available — the TRIUMPH-Outcomes trial is ongoing. See Retatrutide and Heart Health.
When will retatrutide be available?
Retatrutide Phase 3 trials are completing in early 2026. Eli Lilly is expected to submit a New Drug Application to the FDA in late 2026 or early 2027, with potential approval and market availability around mid-to-late 2027. For the latest timeline, see FDA Approval Timeline and Retatrutide Availability.
Sources
- Dr. Dan. "Retatrutide vs Ozempic - This New Weight Loss Drug Changes Everything." Dr. Dan | Obesity Expert. Watch on YouTube
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
- Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). New England Journal of Medicine. DOI: 10.1056/NEJMoa1411892
- Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
- Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
- Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. DOI: 10.1056/NEJMoa2307563
- Eli Lilly. (2025). Lilly's retatrutide achieved significant weight loss and symptom improvement in people with obesity and knee osteoarthritis (TRIUMPH-4). Press release
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
Dr. Dan's video is not medical advice. He consistently encourages viewers to consult with their own healthcare providers. His presentation of the Phase 2 data in this video is largely accurate and well-balanced.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider.
This site is not affiliated with Dr. Dan, Eli Lilly and Company, Novo Nordisk, or any pharmaceutical manufacturer.
Sources
- Retatrutide vs Ozempic (YouTube)
YouTube
- Phase 2 trial (NEJM)
New England Journal of Medicine
Related reading
Retatrutide Results: Weight Loss Data and What to Expect
28.7% average weight loss in Phase 3 — here's the full data breakdown by dose, timeline, and what individual results look like.
Retatrutide Side Effects & Safety
Clinical trial safety data, the new dysesthesia signal, and how side effects compare to existing GLP-1 drugs.
Retatrutide vs Zepbound: What's the Difference?
Same manufacturer, different drugs. Retatrutide adds glucagon agonism for 28.7% vs Zepbound's 22.5% weight loss.
Retatrutide vs Wegovy: Triple Agonist vs GLP-1
Retatrutide produces nearly double the weight loss of Wegovy, but Wegovy is available now with proven cardiovascular protection.
Retatrutide and Heart Health (Cardiovascular Effects)
Early data shows improvements in blood pressure, lipids, and inflammation. Dedicated cardiovascular outcomes trials are underway.